Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Early Phase 1
1(25.0%)
4Total
N/A(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03195257Not ApplicableCompleted

Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes

Role: lead

NCT01739283Not ApplicableCompleted

GIP and GLP-1 in Type 1 Diabetes

Role: lead

NCT02104037Not ApplicableCompleted

Liraglutide in Spinal Fluid

Role: lead

NCT01414556Early Phase 1Completed

GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes

Role: lead

All 4 trials loaded